HOME >> BIOLOGY >> NEWS
Marimastat produces comparable survival rates to chemotherapy in some advanced pancreatic cancer patients

Marimastat, a matrix metalloproteinase inhibitor, offers a similar survival benefit to chemotherapy in patients with non-metastatic pancreatic cancer, but with fewer side effects, reports an international team of researchers from the United States and Britain.

The randomized clinical trial compared the effects of three different doses of marimastat with the chemotherapy drug gemcitabine in 414 patients with advanced pancreatic cancer. During this clinical trial, gemcitabine was approved for use in pancreatic cancer, and is now considered the standard of care.

According to the study, the one-year survival rate for patients with localized cancer was 20 percent for patients given the highest dose of marimastat and 19 percent for patients treated with gemcitabine. Although patients taking gemcitabine reported greater improvements in pain and mood, fewer toxic side effects (e.g., pulmonary complications and nausea) were reported in patients taking marimastat versus gemcitabine (12 percent versus 22 percent, respectively).

Marimastat did not show benefit in lower doses or in patients with metastatic pancreatic cancer. The one-year survival rate for patients taking lower doses of marimastat was 14 percent.

Researchers say marimastat appears to benefit some non-metastatic patients and suggest the agent be tested in those patients in combination with gemcitabine. "Five years ago, patients with advanced pancreatic cancer did not have any good treatment options, but gemcitabine and newly engineered drugs like marimastat are giving us hope," says the study leader Simon Bramhall, from the Queen Elizabeth Hospital, Birmingham, England. "These clinical trial results are encouraging and suggest that targeted molecular therapy may benefit some patients."

Matrix metalloproteinase inhibitors restrict the growth and spread of solid tumors by blocking blood vessel growth to the site of tumors. Marimastat is also being tested in ovarian a
'"/>

Contact: Carrie Bittman
bittmanc@asco.org
703-299-1016
American Society of Clinical Oncology
30-Jul-2001


Page: 1 2

Related biology news :

1. Genetic modification of linseed produces healthier omega 3 and 6 fatty acids
2. Spontaneous mutation produces new MAO A/B knockout mouse
3. Synthetic hormone used in contraceptives and HRT produces negative effects in monkey studies
4. Tigecycline - Candidate antibiotic produces 74 percent cure rate in cSSSI patients
5. First genetic comparison of purebred domestic dogs produces surprises
6. Biological computer diagnoses cancer and produces drug in a test tube
7. High-fat fast-food breakfast produces rush of inflammatory factors into blood stream, UB study finds
8. Oil exploitation in Ecuadors Amazon basin produces a public health emergency
9. Method produces uniform, self-assembled nanocells
10. Scientists develop plant that produces potential anti-carcinogen
11. Brains master molecule produces same behavior in mice from three different psychostimulant drugs

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:1/7/2016)... Jan. 7, 2016 This BCC Research report ... biometric technologies and devices, identifying newer markets and exploring ... types of biometric devices. Includes forecast from 2015 to ... newer markets and explore the expansion of the present ... each type of biometric technology, determine its current market ...
(Date:1/7/2016)...  A United States District Court in ... country to interpret a biometric privacy statute in a ... the photo website Shutterfly brought by the law firm Carey ... vs. SHUTTERFLY, INC.; and THISLIFE, INC ( N.D. Ill ... the Illinois Biometric Privacy Act by collecting and scanning ...
(Date:1/6/2016)... Jan. 6, 2016 Based on its ... & Sullivan recognizes MorphoTrak, LLC, a U.S. subsidiary ... Frost & Sullivan Company of the Year Award. ... technology, Morpho Wave™ , has consolidated the company,s ... biometrics market. Morpho Wave is a highly ...
Breaking Biology News(10 mins):
(Date:2/5/2016)... Australian-US drug discovery and development company, Novogen Limited (ASX:NRT; NASDAQ: ... Chairman, Mr John O,Connor , and new Deputy Chairman, ... James Garner , has also been formally appointed to the ... Iain Ross , will resume his role on the ... , has also been formally appointed to the Board as ...
(Date:2/4/2016)... Falls Church, VA (PRWEB) , ... ... ... a first-year cybersecurity conference presented by Bloomsburg University’s Digital Forensics Club, takes ... Bloomsburg, PA. The two-day event features 20+ speakers and activities such as ...
(Date:2/4/2016)... N.J. , Feb. 4, 2016 ContraVir ... focused on the development and commercialization of targeted antiviral ... CEO & Investor Conference 2016, to be held February ... Source Capital Group,s 2016 Disruptive Growth & Healthcare Conference, ... on February 10-11, 2016. James Sapirstein , ...
(Date:2/4/2016)... ... 2016 , ... Many of the engineers at FireflySci, Inc. have been manufacturing ... apart from other cuvette manufacturers is their supercharged customer service and their extensive database ... this steady flow of inside information, they have recently revamped their manufacturing techniques to ...
Breaking Biology Technology:
Cached News: